0.05
-0.0109(-19.33%)
Currency In USD
| Previous Close | 0.06 |
| Open | 0.05 |
| Day High | 0.06 |
| Day Low | 0.05 |
| 52-Week High | 0.06 |
| 52-Week Low | 0.05 |
| Volume | 54,239 |
| Average Volume | 32,275.85 |
| Market Cap | 13.3M |
| PE | -0.03 |
| EPS | -1.73 |
| Moving Average 50 Days | 0.06 |
| Moving Average 200 Days | 0.06 |
| Change | -0.01 |
FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
GlobeNewswire Inc.
Oct 14, 2025 12:00 PM GMT
Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the FDA’s 505(b)(2) regulatory pathway KANSAS CITY, Kan., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cingulate I
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
GlobeNewswire Inc.
Sep 17, 2025 12:45 PM GMT
Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA ApprovalKANSAS CITY, Kan., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision
Cingulate Provides Management Team Update
GlobeNewswire Inc.
Aug 15, 2025 1:00 PM GMT
Jennifer Callahan, Chief Financial Officer, appointed Interim CEO Board member, Jay Roberts appointed Executive Chairman KANSAS CITY, Kan., Aug. 15, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CING) The Board of Directors of Cingulate Inc. (“Cingulate”) ann